A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Authors

Satya Das

Satya Das

Vanderbilt University Medical Center, Nashville, TN

Satya Das , Liping Du , Aimee Schad , Shikha Jain , Aaron Jessop , Chirayu Shah , David Eisner , Dana Backlund Cardin , Kristen Keon Ciombor , Laura Williams Goff , Marques Bradshaw , Dominique Delbeke , Martin P. Sandler , Jordan Berlin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Neuroendocrine/Carcinoid

Track

Neuroendocrine/Carcinoid

Sub Track

Therapeutics

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 363)

DOI

10.1200/JCO.2021.39.3_suppl.363

Abstract #

363

Poster Bd #

Online Only

Abstract Disclosures